KRAS and non-small cell lung carcinoma: HS primarily contains emodin and eugenol (Xiang and Ay, 2014), both demonstrating mechanistic relevance: emodin suppresses KRAS-mutant NSCLC proliferation by downregulating sPLA2-IIa and NF-κB pathway expression, positioning it as a potential therapeutic target (Zhang et al., 2022), while eugenol exerts antitumor activity via TRIM59-mediated inhibition of NF-κB signaling (Cui et al., 2019).